Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma

The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases...

Descripción completa

Detalles Bibliográficos
Autores principales: Teppert, Karin, Winter, Nora, Herbel, Vera, Brandes, Caroline, Lennartz, Simon, Engert, Fabian, Kaiser, Andrew, Schaser, Thomas, Lock, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603253/
https://www.ncbi.nlm.nih.gov/pubmed/37901209
http://dx.doi.org/10.3389/fimmu.2023.1178060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603253/
https://www.ncbi.nlm.nih.gov/pubmed/37901209
http://dx.doi.org/10.3389/fimmu.2023.1178060

Ejemplares similares